Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Eur J Neurol ; 31(8): e16313, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38676444

RESUMO

BACKGROUND AND PURPOSE: This systematic review examines the effectiveness of motivational interviewing (MI) on medication adherence for preventing recurrent stroke and transient ischemic attack (TIA). METHODS: MEDLINE (via PubMed), CINAHL, PsycINFO, CENTRAL, and ClinicalTrials.gov were searched from inception to 12 June 2023. Randomized controlled trials comparing MI with usual care or interventions without MI in participants with any stroke type were identified and summarized descriptively. Primary outcome was medication adherence. Secondary outcomes were quality of life (QoL) and different clinical outcomes. We assessed risk of bias with RoB 2 (revised Cochrane risk-of-bias tool) and intervention complexity with the iCAT_SR (intervention Complexity Assessment Tool for Systematic Reviews). RESULTS: We screened 691 records for eligibility and included four studies published in five articles. The studies included a total of 2751 participants, and three were multicentric. Three studies had a high risk of bias, and interventions varied in complexity. Two studies found significantly improved medication adherence, one at 9 (96.9% vs. 88.2%, risk ratio = 1.098, 95% confidence interval = 1.03-1.17) and one at 12 months (97.0% vs. 95.0%, p = 0.026), but not at other time points, whereas two other studies reported no significant changes. No significant differences were found in QoL or clinical outcomes. CONCLUSIONS: Evidence on MI appears inconclusive for improving medication adherence for recurrent stroke and TIA prevention, with no benefits on QoL and clinical outcomes. There is a need for robustly designed studies and process evaluations of MI as a complex intervention for people with stroke. REGISTRATION: PROSPERO (CRD42023433284).


Assuntos
Ataque Isquêmico Transitório , Adesão à Medicação , Entrevista Motivacional , Ensaios Clínicos Controlados Aleatórios como Assunto , Prevenção Secundária , Acidente Vascular Cerebral , Humanos , Ataque Isquêmico Transitório/prevenção & controle , Ataque Isquêmico Transitório/tratamento farmacológico , Entrevista Motivacional/métodos , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Acidente Vascular Cerebral/prevenção & controle , Acidente Vascular Cerebral/tratamento farmacológico , Prevenção Secundária/métodos , Recidiva
2.
J Evid Based Med ; 16(3): 294-302, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37674307

RESUMO

OBJECTIVE: To evaluate the reporting of abstracts of Cochrane Reviews according to PRISMA-A and to investigate a possible association with the abstract´s length. METHODS: This is a retrospective, observational study based on all Cochrane Reviews indexed in Medline (via PubMed) until November 18, 2022. In the second part, a random sample of 440 abstracts was drawn, in which PRISMA-A adherence was assessed by two independent reviewers. Analyses were stratified by the year of publication and the number of words. RESULTS: Overall, the median number of words of the 15,188 included abstracts was 469 (IQR 389-686 words), steadily increasing from 353 words in 2000 to 838 words in 2022, with less than one percent of the abstracts in 2022 having ≤ 300 words (in 2000: 30.7%). Analyses on PRISMA-A adherence in the random sample showed a mean score of 6.1 out of 12 fully reported items. Stratified by year, PRISMA-A adherence increased, with higher word counts in 2000-2010 and 2011-2015, while there was no difference in PRISMA-A adherence by abstract length in 2016-2022. CONCLUSION: Over the years, abstracts of Cochrane Reviews have become longer, running up to 1000 words. This conflicts with the Cochrane Handbook, which recommends a maximum length of 400 until it was aligned with MECIR in 2019, which has recommended a length of <700 words since 2012 but allows up to 1000 words. It is debatable whether such long abstracts meet the key goals of abstracts of being informative, accurate, appealing, and concise.


Assuntos
Projetos de Pesquisa , Literatura de Revisão como Assunto
3.
Int J Nurs Stud ; 145: 104555, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37421830

RESUMO

BACKGROUND: This systematic review examines the prevalence of indwelling urinary catheters in nursing home residents. METHODS: MEDLINE via PubMed, CINAHL, and EMBASE were searched from inception to 9 August 2022. Cross-sectional studies and longitudinal studies with cross-sectional analyses reporting catheter prevalence in nursing home residents were identified and summarized descriptively. Study quality was assessed using the Joanna Briggs Institute's tool. RESULTS: Sixty-seven studies (92.5 % cross-sectional) were included. The reported number of included residents ranged from 73 to 110,656. The median catheter prevalence was 7.3 % (interquartile range 4.3-10.1 %; n = 65 studies). It was higher in Germany (10.2 % [9.7-12.8 %]; n = 15) than in the United States of America (9.3 % [6.3-11.9 %]; n = 9), United Kingdom (6.9 % [4.8-8.5 %]; n = 7), and Sweden (7.3 % [6.4-7.9 %]; n = 6). Furthermore, it was higher among men (17.0 % [16.0-26.0 %]) than among women (5.3 % [4.0-9.5 %]) (n = 9). Only one study investigated differences by age. The prevalence was higher for transurethral (5.7 % [5.6-7.2 %]; n = 12) than for suprapubic (1.2 % [0.6-2.5 %]; n = 13) catheters. Most catheterized residents were long-term catheterized (n = 6) and had their catheter changed within 3 months (n = 2). Symptomatic urinary tract infections were more common among catheterized than among non-catheterized residents (n = 4). DISCUSSION: Catheter prevalence in nursing home residents varies between studies and countries. Prevalence differences by sex, age, and catheter type as well as duration of catheterization, catheter change intervals, and catheter-associated urinary tract infections are rarely reported because most studies do not primarily focus on catheters. Future studies should focus on the circumstances of urinary catheter use and care in nursing home residents. REGISTRATION AND FUNDING: PROSPERO (29 August 2022; CRD42022354358); no funding.


Assuntos
Cateteres de Demora , Infecções Urinárias , Masculino , Humanos , Feminino , Estados Unidos , Cateteres de Demora/efeitos adversos , Cateteres Urinários/efeitos adversos , Cateterismo Urinário/efeitos adversos , Prevalência , Estudos Transversais , Infecções Urinárias/epidemiologia , Infecções Urinárias/etiologia , Casas de Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...